References | Boothe et al.[11] | Schwartz-Porsche et al.[15] | Morton et al.[31] | Heynold et al.[36] | Tipold et al.[14] | |
---|---|---|---|---|---|---|
AED evaluated | Phenobarbital | |||||
2 nd AED | - | - | - | - | - | - |
3 rd AED | - | - | - | - | - | - |
4 th AED | - | - | - | - | - | - |
No of dogs | 20 | 15 | 44 | 7 | 37 | After exclusion: 88 |
Before exclusion: 102 | ||||||
Period of treatment (months) | approx. 6 | mean 15; range 7.3-32 | mean 5.9 +/−0.4 | Unclear | mean 50.4; range 8-18 | 5 |
Dose of AED(s) (mg/kg) | mean 4.11; range 3.9-4.9 PO BID | Range 5–17 PO SID | mean 6; range 4–13 PO SID | median 180; mean 283; range 60–900 PO SID | mean 2.5 PO BID | 2-6 PO BID |
Pre-treatment SF (seizures/month) | mean 4.4 +/− 6.3 (recorded over a period of at least 6 weeks) | NA | mean 1.71 (recorded over a period of 9 m) | median 12; mean 14.3; range 4–28 (period not reported) | mean 8 seizures in total (period not reported) | 2.4 |
Post-treatment SF (seizures/month) | mean 0.4 +/− 0.9 | NA | mean 0.59 | median 1; mean 1; range 0-4 | mean 0.9 | 1.1 |
No of dogs that were failures | - | 3/15 (20%) | 12/44 (27%) | 1/7 (14%) | 10/37 (27%) | - |
No of dogs with >0% - <50% reduction in SF | 2/20 (10%) | - | - | 3/7 (43%) | - | - |
No of dogs with ≥50% - <100% reduction in SF | 1/20 (5%) | 6/15 (40%) | 28/44 (64%) | - | 16/37 (43%) | After exclusion: 22/88 (25%) |
Before exclusion: 25/102 (24%) | ||||||
No of dogs with 100% reduction in SF | 17/20 (85%) | 6/15 (40%) | 9/44 (20%) | 3/7 (43%) | 11/37 (30%) | After exclusion: 51/88 (51%) |
Before exclusion: 56/102 (55%) | ||||||
No of dogs with >30% reduction in SF | - | 12/15 (80%) | 37/44 (84%) | 4/7 (57%) | 27/37 (73%) | - |
95% CI successfully treated cases | 77% - 100% | 60% - 100% | 73% - 95% | 6% - 80% | 59% - 87% | After exclusion: 75% - 91% |
Before exclusion: 71% - 87% | ||||||
Overall evidence for/against recommending the use of an AED | Good evidence for recommending the use of phenobarbital as a monotherapy AED. |